nickcooper

Exosomes are the smallest and most characteristic of extracellular vesicles and contain a variety of biological information, including proteins, lipids, DNA, mRNA, and microRNA. These biomolecules are involved in regulating various life activities such as signal transduction, proliferation, migration, and angiogenesis among tumor cells. Exosomes are not only a new biological marker assay, but also provide potential molecular therapeutic targets and are expected to be a carrier for anti-brain tumor drug delivery.Exosome development services for brain tumorsThe use of peripheral blood biomarkers is particularly important to assist in determining brain tumor recurrence and evaluating treatment response. Exosomes readily cross the blood-brain barrier into and out of the central nervous system. We can detect specific sequence changes in DNA isolated from brain tumor patient samples (e.g., peripheral blood extracellular vesicles from glioma patients) to identify potential biological markers. RNAs (including miRNAs and lncRNAs) obtained from peripheral blood or body fluid exosomes are more abundant and tumor-specific. Therefore, we looked for proteins that were highly expressed by observing the expression profiles of exosomal miRNA and lncRNA in brain tumors (glioblastoma) compared with normal tissues as biological markers for the diagnosis of glioblastoma.Service for isolation and identification of exosomes of brain tumor originWe select different exosome isolation methods for different isolation purposes, including the isolation and purification of brain tumor-derived exosomes from biological fluid samples such as cell culture supernatants and patient plasma using ultrafast differential centrifugation, ultrafiltration, OptiPrep density gradient centrifugation, and immunoprecipitation (IP). With appropriate methods, we can isolate and obtain relatively uniform-sized microvesicular populations with high specificity and no impact on the subsequent analysis of the results.We understand the biological activity of exosomes by measuring the size of vesicle particles and the expression levels of specific proteins TSG101, ALIX, or myelin proteolipid protein (PLP) on their membrane surface. We can combine multiple proteins as exosome markers, such as ALIX, TSG101, CD63, CD60, CD9, and CD81, and then use mass spectrometry analysis to perform a comprehensive screening of the proteome of exosomes, and observe the size and morphology of exosomes by fluorescence and electron microscopy.Drug delivery system development services for brain tumors based on exosomesExosomes have high stability, good biocompatibility, low immunogenicity, and can cross the blood-brain barrier, making them the best carrier for targeted drug delivery. We can assemble drugs in exosomes derived from glioma cell line U⁃87 by room temperature incubation and ultrasonic treatment to increase its toxicity. In addition to their ability to target the delivery of anti-brain tumor drugs and facilitate their uptake, exosomes may also play a role in reversing drug resistance in brain tumor cells. This provides us with new strategies to utilize these properties of exosomes for the treatment of brain tumors.

Neoantigen is a kind of tumor-specific antigen derived from non-synonymous mutations, which plays an important role in the killing of tumor by immune cells, and effective anti-tumor immunity is directly related to tumor neoantigen-specific T cells. Neoantigens are highly immunogenic and specific, not expressed in normal tissues, and bypass the central thymus without immune tolerance, making them ideal targets for anti-tumor immunotherapy. With the development of next-generation sequencing technology and the application of machine learning algorithms, it has become feasible to predict neoantigens, which can detect the differences between tumor cells and normal cells, and determine the best neoantigens to incorporate into tumor vaccines. The individualized nature of neoantigen immunotherapy typically requires 10-30 GMP-grade peptides (selected as neoantigens) to be manufactured for each patient. Peptide neoantigen therapy constitutes a significant paradigm-shift in GMP peptide manufacturing due to the need for multiple peptide sequence targets, rapid peptide synthesis, and small-scale manufacturing (gram-scale).

Introduction of TME biomarker detection servicesTumor markers appear along with tumors and are usually increased in amounts of proteins, oncogenes, tumor suppressor genes and their related products in the form of antigens, enzymes, receptors, hormones or metabolites. It is produced and secreted by tumor cells, or is part of the released tumor cell structure. It exists only in tumor cells and is often released into serum or other body fluids, which can reflect the presence of tumors in the body to a certain extent.The detection and analysis of tumor biomarkers is the core of personalized and precise tumor therapy, which can determine the occurrence, development and prognosis of tumors. Complete and comprehensive detection is of great significance for elucidating the effect of anti-tumor drugs or drug resistance mechanisms, and screening characteristic populations.ServicesAt Alfa Oncology, we have established a mature tumor microenvironment center technology platform, with a professional team and mature technology, as well as years of experience in tumor and microenvironment research. We provide global customers with comprehensive testing services based on ELISA, FACS, pathology and molecular, including Western Blot, Q-PCR, RNAscope and other technical services. It can carry out experiments ranging from protein and mRNA extraction, quantification, molecular sequencing, etc., to support the one-stop research needs of animal model tissue samples, and help you to analyze biomarkers at the molecular dimension.Service contentService typeSpecific service contentELISA testing servicesMethod development and established method validation (Non-GLP)Large and small animal PK sample analysis serviceADA/Nab analysis servicesBiomarker quantitative analysis serviceFACS inspection servicesReceptor occupation (RO) detection serviceTumor infiltrating lymphocyte (TIL) detection serviceHistopathology servicesImmunohistochemistry (IHC) servicesHematoxylin-eosin staining (HE) serviceMulticolor immunofluorescence (multi-IF) serviceRNAscopeMolecular testing servicesSanger sequencingRT-PCR/Q-PCR serviceGenotyping serviceMolecular typing serviceImmunotyping service